Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Mallinckrodt Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853892
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 17, 2026, 3:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

NCT00879645
View directory record Official record
Conditions
Renal Impairment
Interventions
Sodium Sulfide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Corticotropin 80Unit/Ml Repository Injection
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass

NCT00585013
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Nitric Oxide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

NCT04123548
View directory record Official record
Conditions
Deep Partial-thickness Burn
Interventions
StrataGraft skin tissue
Biological
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 17, 2026, 3:41 AM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02767349
View directory record Official record
Conditions
Acute Pain
Interventions
MNK-155
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain

NCT01451385
View directory record Official record
Conditions
Osteoarthritis, Low Back Pain
Interventions
COV795
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Tucson, Arizona • Anaheim, California • Buena Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises

NCT00094887
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

NCT02633046
View directory record Official record
Conditions
Idiopathic Focal Segmental Glomerulosclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

NCT00931632
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Days to 14 Days
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

NCT02766777
View directory record Official record
Conditions
Constipation - Functional
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Fayetteville, Arkansas • Peoria, Illinois • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain

NCT00564486
View directory record Official record
Conditions
Pain
Interventions
IV Placebo, IV Acetaminophen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Sheffield, Alabama • Phoenix, Arizona • Arcadia, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 17, 2026, 3:41 AM EDT
Recruiting Phase 3 Interventional

NO During CPB in Neonates to Reduce Risk of AKI

NCT04216927
View directory record Official record
Conditions
AKI, CHD - Congenital Heart Disease, Surgery
Interventions
Nitric Oxide, Oxygen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 31 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)

NCT02369211
View directory record Official record
Conditions
Prostatectomy, Pain
Interventions
Acetaminophen (Ofirmev), Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 17, 2026, 3:41 AM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Not applicable Interventional Results available

U.S. Study of Fibrocaps in Surgical Hemostasis

NCT01256164
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Fibrocaps (fibrin sealant), Gelfoam
Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 4 Interventional

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ACTHar
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 17, 2026, 3:41 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

NCT00054613
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Little Rock, Arkansas • Gainesville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 17, 2026, 3:41 AM EDT
Terminated Phase 2 Interventional

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

NCT02542215
View directory record Official record
Conditions
Oral Mucositis
Interventions
Cobiprostone, Placebo, Standard Care - Chemotherapy, Standard Care - Radiation
Drug · Radiation
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
76
States / cities
Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 17, 2026, 3:41 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02508935
View directory record Official record
Conditions
Acute Pain
Interventions
XARTEMIS XR
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 17, 2026, 3:41 AM EDT
Completed No phase listed Observational

Registry of Preterm Newborns With Severe Pulmonary Hypertension

NCT03310346
View directory record Official record
Conditions
Pulmonary Hypertension, Preterm Infant
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Minutes to 45 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 17, 2026, 3:41 AM EDT